Veeva Systems (NYSE:VEEV) Rating Lowered to “Neutral” at Citigroup

Veeva Systems (NYSE:VEEV) was downgraded by analysts at Citigroup from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. They presently have a $176.00 price target on the technology company’s stock, down from their previous price target of $291.00. Citigroup’s target price points to a potential upside of 16.23% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. UBS Group lifted their price objective on Veeva Systems from $200.00 to $220.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. KeyCorp reiterated a “sector weight” rating on shares of Veeva Systems in a research note on Friday, December 12th. Piper Sandler decreased their price objective on Veeva Systems from $355.00 to $285.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Truist Financial reiterated a “buy” rating and issued a $262.00 price objective (down from $275.00) on shares of Veeva Systems in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada decreased their price objective on Veeva Systems from $330.00 to $275.00 and set an “outperform” rating for the company in a research note on Thursday, March 5th. Sixteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.70.

Veeva Systems Trading Down 3.6%

Shares of NYSE:VEEV opened at $151.43 on Friday. The business has a 50-day moving average price of $180.52 and a 200 day moving average price of $229.62. The company has a market capitalization of $24.73 billion, a price-to-earnings ratio of 27.99, a PEG ratio of 0.99 and a beta of 1.10. Veeva Systems has a 12-month low of $148.05 and a 12-month high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, March 4th. The technology company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $835.95 million during the quarter, compared to the consensus estimate of $810.95 million. Veeva Systems had a return on equity of 13.80% and a net margin of 28.44%.The company’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period last year, the company earned $1.74 EPS. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. As a group, equities research analysts predict that Veeva Systems will post 4.35 earnings per share for the current fiscal year.

Veeva Systems announced that its board has authorized a stock repurchase program on Monday, January 5th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the technology company to reacquire up to 5.5% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of Veeva Systems stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total transaction of $231,430.00. Following the transaction, the insider owned 23,204 shares of the company’s stock, valued at $5,370,101.72. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Veeva Systems by 3.1% during the third quarter. Vanguard Group Inc. now owns 15,429,231 shares of the technology company’s stock worth $4,596,522,000 after buying an additional 457,806 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Veeva Systems by 4.1% in the third quarter. Alliancebernstein L.P. now owns 5,941,631 shares of the technology company’s stock valued at $1,770,071,000 after purchasing an additional 235,983 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Veeva Systems by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 3,870,293 shares of the technology company’s stock valued at $863,978,000 after purchasing an additional 23,416 shares during the period. State Street Corp increased its holdings in shares of Veeva Systems by 2.4% in the fourth quarter. State Street Corp now owns 3,589,425 shares of the technology company’s stock valued at $801,267,000 after purchasing an additional 85,695 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Veeva Systems by 4.8% in the third quarter. JPMorgan Chase & Co. now owns 3,476,258 shares of the technology company’s stock valued at $1,035,622,000 after purchasing an additional 159,984 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Analyst upgrade — A Seeking Alpha note upgraded Veeva to a Buy, arguing the recent share-price decline has reset valuation and that Veeva’s regulated, life‑sciences‑focused software is resilient to AI disruption; the report cites mid‑teens revenue/billings growth and healthy margin guidance. Veeva Systems: Not A Likely Victim Of Total AI Disruption – Buy The Dip (Upgrade)
• Positive Sentiment: Product/partnership progress — Veeva expanded its regulatory intelligence (RIM) capabilities via a partnership with RegASK to add real‑time regulatory intelligence and AI-enabled decision support, which should support customer retention and upsell. RegASK & Veeva Systems Partner to Boost RIM Intelligence Capabilities
• Positive Sentiment: Underlying fundamentals — Veeva reported a recent quarter with an EPS and revenue beat and mid‑teens revenue growth; management set FY27 targets implying continued solid profitability and billings growth, supporting the longer‑term thesis.
• Neutral Sentiment: Increased investor attention — Several market writeups and roundups are highlighting Veeva as a fall‑from‑grace name and discussing buy/hold/sell options; this raises visibility but not a clear directional catalyst. Veeva Systems (VEEV): Buy, Sell, or Hold Post Q4 Earnings?
• Neutral Sentiment: Zacks / news flow summaries — Multiple short pieces summarize Veeva’s recent results, guidance and market reaction; useful for context but not immediate drivers. Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Big analyst downgrade — Citigroup cut Veeva from Buy to Neutral and slashed its price target (from $291 to $176), citing broader software/AI durability concerns; that downgrade is the proximate catalyst for today’s heavier selling. Benzinga – Citigroup downgrade
• Negative Sentiment: Sector skepticism on AI impact — Citi’s broader research downgrades of several software names and commentary that AI agents could compress demand for legacy SaaS products have pressured sentiment across the group, worsening outflows into Veeva. 3 Software Stocks Citi Just Downgraded as Slump Refuses to Let Up

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.